Capacity development to facilitate access to fexinidazole

Capacity development to facilitate access to fexinidazole

Objective: Support fexinidazole access for gambiense sleeping sickness patients through capacity strengthening activities at national and local levels of the health system in line with the WHO treatment guidelines.


Project start: 2020

The project, known as FEX-g-HAT, is facilitating the delivery and uptake of fexinidazole, the first all-oral treatment for sleeping sickness, into selected African endemic countries through strengthened health care capacity and coordination via: the HAT Platform, a clinical research, training and access-supporting network of over 120 institutions; through trainings in the use of new tools; and reinforced pharmacovigilance channels for introduction of the new treatment.

The FEX-g-HAT project brings together a consortium of experts: DNDi, the National Control Programmes for Human African Trypanosomiasis of the Democratic Republic of Congo and Guinea, the Research Institute for Development (IRD), and the Institute of Tropical Medicine Antwerp.

Project updates


In 2020, training activities of health care providers were carried out focussing on serological screening, updating new HAT treatment guidelines and pharmacovigilance, to support improved detection and early treatment of gambiense sleeping sickness. Activities to ensure effective tracking and to facilitate access to fexinidazole were also undertaken.

Furthermore, in the DRC, 26 focal points from three regional pharmacovigilance centres have been trained.

This project (grant CSA2018HS-2526) is part of the European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union.

EDCTP logo
EU logo